Physician profile
Caroline Hwang
NPI 1811102718
$1,944.06
in general payments reported to CMS, 2019-2025
14 companies · $75.91 in 2025
The $75.91 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.55 · 2020: $47.46 · 2021: $363 · 2022: $563 · 2023: $830 · 2024: $24.83 · 2025: $75.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $332 · Education: $300 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $331.75 |
| Education | $300.19 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $840.89 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $300.00 | 2021 | |
| Seagen INC. | $156.99 | 2023 | |
| Janssen Biotech, INC. | $129.62 | 2023 | Erleada |
| Merck Sharp & Dohme LLC | $107.27 | 2019-2025 | Keytruda |
| Daiichi Sankyo INC. | $101.05 | 2020-2023 | Enhertu |
| Genentech USA, INC. | $81.02 | 2019-2023 | Phesgo |
| Astrazeneca Pharmaceuticals LP | $68.08 | 2024-2025 | Enhertu, Lynparza |
| Celgene Corporation | $45.63 | 2022-2023 | Pomalyst |
| Aveo Pharmaceuticals, INC. | $24.37 | 2023 | Fotivda |
| Astellas Pharma US INC | $23.61 | 2023 | Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $23.08 | 2020 | |
| Sumitomo Pharma America, INC. | $22.32 | 2023 | Orgovyx |
| Pfizer INC. | $20.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.